Arjuna Therapeutics

ARJUNA Therapeutics is pleased to announce the award of a prize from the MATWIN International Board at the 2024 MATWIN Congress in Bordeaux, France.

The Phaeo and Para Cancer Charity of the UK and ARJUNA Therapeutics announce their collaboration to develop treatments for rare tumours driven by mutations in the SDH-B gene.

ARJUNA Therapeutics announces that it will be presenting data at the 2023 American Association for Cancer Research meeting in Orlando, Florida, outlining single agent and combinatorial efficacy for its lead asset, Ag5, in Non Small Cell Lung Cancer.

ARJUNA Therapeutics announces the appointment of Mr Jo Williamson as Chief Patient Representative, and advisor to the Scientific Advisory Board (SAB).

ARJUNA Therapeutics, the European biotech start-up, announces the appointment of Dr Robert Barnes to the Board of Directors.

London, Santiago de Compostela ARJUNA Therapeutics announced today that data for Arjuna's preclinical Ag5 program will be presented at the American Association of Cancer Research (AACR) 2021 Annual Meeting.

ARJUNA Therapeutics announces the appointment of Martin Treder, PhD as Chief Scientific Officer. He will lead the development of ARJUNA's lead assets into clinical development and advance the broad pipeline of TMC compounds. Dr.

The Center for Advancing Innovation (CAI) announces that ARJUNA Therapeutics is one of the winners of the Brain Race, an open innovation contest to advance high-impact inventions and solutions to defeat brain tumors.

Santiago de Compostela, Spain and St Anselmo, California, USA